Federal Register / Vol. 83, No. 137 / Tuesday, July 17, 2018 / Notices 33305 

inventory of interlock programs to 

support program management by 

documenting lessons learned and 

identifying solutions to common 

problems. The collected information 

would be from publicly available 

sources such as program websites, and 

from program administrators and staff. 

Administrators would be invited to take 

a 15-minute online self-administered 

questionnaire, and administrators and 

staff would be invited to participate in 

a semi-structured interview over the 

telephone, up to one hour (with one 

interview per program). 

Respondents: Respondents will be 

administrators and staff of alcohol 

ignition interlock programs. There are 

up to 52 interlock programs; with nearly 

one in each state, the District of 

Columbia, and Puerto Rico. 

Estimated Number of Respondents: 

260 (If 52 administrators and four staff 

per program were to respond). 

Estimated Time per Response: The 

expected average completion time for 

the questionnaire is 15 minutes, and for 

the group phone interview it is 60 

minutes. 

Estimate of the Total Annual 

Reporting and Record Keeping Burden 

Resulting from the Collection of 

Information: Participants will incur no 

burden related to annual reporting or 

record keeping due to the collection of 

information. 

Total Estimated Annual Burden 

Hours: A total of 273 hours: The 

estimated burden hours for the 

questionnaire is 13 hours (52 

administrators × .25 hours to take the 

questionnaire), and the estimated 

burden hours for the group interviews is 

260 hours (260 people × 1 hour). 

Frequency of Collection: The 

information collection will be 

administered a single time. 

Previous Notice: A 60-day notice in 

the Federal Register on August 24, 2017 

received three comments. The first 

comment recommended that the 

questionnaire and the topics of the 

group interview be provided ahead of 

time with the managers of each 

program’s transportation department, to 

allow managers the opportunity to 

provide guidance to the staff. NHTSA 

concurs with this request. The second 

request was that the information 

collection should ‘‘not ask for 

judgments’’ about a department. NHTSA 

concurs with this request, as the 

collected information is on features and 

facts of the programs. The third 

comment was that ‘‘other approaches to 

combatting impaired driving’’ warrant 

support. NHTSA concurs with this 

comment. 

Comments are Invited: Comments are 

invited on whether the proposed 

collection of information is (a) necessary 

for the Department’s performance; (b) 

the accuracy of the estimated burden; (c) 

ways for the Department to enhance the 

quality, utility and clarity of the 

information collection; and (d) ways 

that the burden could be minimized 

without reducing the quality of the 

collected information. 

A comment to OMB is most effective 

if OMB receives it within 30 days of 

publication of this notice. 

Authority: The Paperwork Reduction Act 

of 1995; 44 U.S.C. Section 3506(c)(2)(A). 

Issued in Washington, DC, on July 12, 

2018. 

Jeff Michael, 

Associate Administrator, Research and 

Program Development. 

[FR Doc. 2018–15210 Filed 7–16–18; 8:45 am] 

BILLING CODE 4910–59–P 

DEPARTMENT OF TRANSPORTATION 

National Highway Traffic Safety 

Administration 

[Docket No. NHTSA–2018–XXXX] 

Drugs that Impair Safe Driving; 

Request for Comments 

AGENCY: National Highway Traffic 

Safety Administration (NHTSA), 

Department of Transportation (DOT). 

ACTION: Request for comment. 

SUMMARY: NHTSA is reviewing the 

literature on drug use and driving with 

the aim of updating its Drugs and 

Human Performance Fact Sheets that are 

used by the criminal justice community 

and others as they address drugimpaired driving. The current edition of 

the Fact Sheets was released in 2004 

and included information on the 

following drugs: Carisoprodol, cocaine, 

dextromethorphan, diazepam, 

diphenhydramine, gammahydroxybutyrate (GHB), ketamine, 

lysergic acid diethylamide (LSD), 

marijuana, methadone, 

methamphetamine, 

methylenedioxymethamphetamine 

(MDMA), morphine, phencyclidine 

(PCP), toluene, and zolpidem. NHTSA 

welcomes comments and suggestions for 

additional drugs to be considered for 

inclusion in the new edition of the Fact 

Sheets as well as relevant research 

studies that have become available since 

2004 that could be included in the 

updated fact sheets. To the extent 

possible, such comments and 

suggestions should be accompanied by 

information about the drug, including 

the extent of its use, its pharmacology 

and pharmodynamics, and how 

impairing it is for driving, along with 

references. 

DATES: Interested parties are invited to 

submit comments and suggestions on or 

before September 1, 2018. 

FOR FURTHER INFORMATION CONTACT: If 

you have questions about this request 

for comment, please contact Richard 

Compton at NHTSAdruginfo@dot.gov or 

202–366–2699. 

Written Comments: Written 

statements and supporting information 

submitted during the comment period 

will be considered. Please submit all 

written comments no later than 

September 1, 2018, by any of the 

following methods: 

• Federal Rulemaking Portal: Go to 

http://www.regulations.gov. Follow the 

online instructions for submitting 

comments. 

• Mail: Docket Management Facility: 

U.S. Department of Transportation, 1200 

New Jersey Avenue SE, West Building 

Ground Floor, Room W12–140, 

Washington, DC 20590–0001. 

• Hand Delivery or Courier: 1200 

New Jersey Avenue SE, West Building 

Ground Floor, Room W12–140, 

Washington, DC 20590–0001, between 9 

a.m. and 5 p.m. ET, Monday through 

Friday, except Federal Holidays. 

• Fax: 202–366–1767. 

Instructions: All submissions must 

include the agency name and docket 

number. Note that all comments 

received will be posted without change 

to http://www.regulations.gov, including 

any personal information provided. 

Please see the Privacy Act discussion 

below. 

Docket: For access to the docket go to 

http://www.regulations.gov at any time 

or to 1200 New Jersey Avenue SE, West 

Building, Ground Floor, Room W12– 

140, Washington, DC 20590, between 9 

a.m. and 5 p.m., Monday through 

Friday, except Federal Holidays. 

Telephone: 202–366–9826. 

Privacy Act: Anyone is able to search 

the electronic form of all comments 

received into any of our dockets by the 

name of the individual submitting the 

comment (or signing the comment, if 

submitted on behalf of an association, 

business, labor union, etc.). You may 

review DOT’s complete Privacy Act 

Statement in the Federal Register 

published on April 11, 2000 (Volume 

65, Number 70; Pages 19477–78), or you 

may visit http://www.regulations.gov/ 

privacy.html. 

Confidential Business Information: If 

you wish to submit any information 

under a claim of confidentiality, you 

should submit three copies of your 


daltland on DSKBBV9HB2PROD with NOTICES
33306 Federal Register / Vol. 83, No. 137 / Tuesday, July 17, 2018 / Notices 

complete submission, including the 

information you claim to be confidential 

business information, to the Chief 

Counsel, NHTSA, 1200 New Jersey Ave. 

SE, W41–326, Washington DC 20590. In 

addition, you should submit two copies, 

from which you have deleted the 

claimed confidential business 

information, to Docket Management at 

the address given above. When you send 

a comment containing information 

claimed to be confidential business 

information, you should submit a cover 

letter setting forth the information 

specified in our confidential business 

information regulation (49 CFR part 

512). 

SUPPLEMENTARY INFORMATION: 

Background 

In the early 2000s, NHTSA convened 

a panel of international experts on drugimpaired driving to review 

developments in the field of drugs and 

human performance and to identify the 

specific effects that both high priority 

illicit and prescription drugs have on 

driving. The experts represented the 

fields of psychopharmacology, 

behavioral psychology, drug chemistry, 

forensic toxicology, medicine, and law 

enforcement. That effort resulted in the 

publication of a document entitled 

Drugs and Human Performance Fact 

Sheets (DOT HS 809 725) in June 2004. 

Each Fact Sheet covered one of the 

selected sixteen drugs that impair 

driving. The selected drugs included 

over-the-counter medications such as 

dextromethorphan and 

diphenhydramine; prescription 

medications such as carisoprodol, 

diazepam, and zolpidem; and abused 

and/or illegal drugs such as cocaine, 

GHB, ketamine, LSD, marijuana, 

methadone, methamphetamine, MDMA, 

morphine, PCP, and toluene. Each 

individual drug Fact Sheet covered 

information regarding drug chemistry, 

usage and dosage information, 

pharmacology, drug effects, effects on 

driving, drug evaluation and 

classification, and the panel’s 

assessment of driving risks. More 

specifically, the Fact Sheets provided 

details on the physical description of 

the drug, synonyms, and 

pharmaceutical or illicit sources; 

medical and recreational uses, 

recommended and abused doses, typical 

routes of administration, and potency 

and purity; mechanism of drug action 

and major receptor sites; drug 

absorption, distribution, metabolism 

and elimination data; blood and urine 

concentrations; psychological and 

physiological effects, and drug 

interactions; drug effects on 

psychomotor performance effects; 

driving simulator and epidemiology 

studies; and drug recognition evaluation 

profiles. Each Fact Sheet concludes with 

general statements about the drugs’ 

ability to impair driving performance. A 

list of key references and recommended 

reading was also provided for each drug. 

Since 2004, new research on these 

and other impairing drugs has become 

available. As a result, NHTSA plans to 

evaluate whether additional drugs that 

impair driving should be included in 

the Fact Sheets and to add them as 

appropriate, as well as to update 

information on the effects of the sixteen 

aforementioned drugs on driving. 

NHTSA will base the revised Fact 

Sheets on the state of current scientific 

knowledge. The agency intends to 

design the revised Fact Sheets to 

continue to provide practical guidance 

to toxicologists, pharmacologists, law 

enforcement officers, attorneys, and the 

general public to use in the evaluation 

of future cases. 

In order to assist on the development 

of the new edition of the Fact Sheets, 

NHTSA invites comments and 

suggestions from the general public on 

additional drugs as well as relevant 

research studies that have become 

available since 2004 that could be 

included in the updated fact sheets. To 

the extent possible, such comments and 

suggestions should be accompanied by 

information about the drug, including 

the extent of its use, its pharmacology 

and pharmodynamics, and how 

impairing it is for driving, along with 

references. 

Authority: 44 U.S.C. Section 3506(c)(2)(A). 

Issued in Washington, DC, on July 12, 

2018. 

Jeff Michael, 

Associate Administrator, Research and 

Program Development. 

[FR Doc. 2018–15209 Filed 7–16–18; 8:45 am] 

BILLING CODE 4910–59–P 

DEPARTMENT OF TRANSPORTATION 

National Highway Traffic Safety 

Administration 

[U.S. DOT Docket No. NHTSA–2018–0060] 

Reports, Forms, and Record Keeping 

Requirements 

AGENCY: National Highway Traffic 

Safety Administration (NHTSA), DOT. 

ACTION: Request for public comment on 

proposed collection of information. 

SUMMARY: Before a Federal agency can 

collect certain information from the 

public, it must receive approval from 

the Office of Management and Budget 

(OMB). Under procedures established 

by the Paperwork Reduction Act of 

1995, before seeking OMB approval, 

Federal agencies must solicit public 

comment on proposed collections of 

information, including extensions and 

reinstatements of previously approved 

collections. This document describes 

the collection of information for which 

NHTSA intends to seek OMB approval. 

DATES: Comments must be received on 

or before September 17, 2018. 

ADDRESSES: You may submit comments 

identified by DOT Docket Number 

NHTSA–2018–0060 using any of the 

following methods: 

Electronic submissions: Go to http://

www.regulations.gov. Follow the online 

instructions for submitting comments. 

Mail: Docket Management Facility, 

M–30, U.S. Department of 

Transportation, 1200 New Jersey 

Avenue SE, West Building Ground 

Floor, Room W12–140, Washington, DC 

20590. 

Hand Delivery: West Building Ground 

Floor, Room W12–140, 1200 New Jersey 

Avenue SE, Washington, DC, between 9 

a.m. and 5 p.m., Monday through 

Friday, except Federal holidays. 

Fax: 1–202–493–2251. 

Instructions: Each submission must 

include the agency name and the docket 

number for this Notice. Note that all 

comments received will be posted 

without change to http://

www.regulations.gov, including any 

personal information provided. 

FOR FURTHER INFORMATION CONTACT: 

Mary Byrd, Contracting Officer’s 

Representative, Office of Behavioral 

Safety Research (NPD–320), National 

Highway Traffic Safety Administration, 

1200 New Jersey Avenue SE, 

Washington, DC 20590. Ms. Byrd’s 

phone number is 202–366–5595, and 

her email address is mary.byrd@dot.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995, 

before an agency submits a proposed 

collection of information to OMB for 

approval, it must publish a document in 

the Federal Register providing a 60-day 

comment period and otherwise consult 

with members of the public and affected 

agencies concerning each proposed 

collection of information. The OMB has 

promulgated regulations describing 

what must be included in such a 

document. Under OMB’s regulations (5 

CFR 1320.8(d)), an agency must ask for 

public comment on the following: 

(i) Whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information will have practical utility; 


daltland on DSKBBV9HB2PROD with NOTICES